News Tocagen’s brain tumour candidate gets PRIME designation An early-stage drug candidate for hard-to-treat brain tumours has been granted special ‘PRIME’ status by the European Medicines Agency.
News Immunotherapy for brain cancer gets European PRIME status Latest addition to EMA's fast-track for cutting edge drugs
Articles Europe launches new PRIME fast-track for promising medicines Andrew McConaghie reports on a newly-launched plan to speed up access to groundbreaking new medicines in Europe.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.